[go: up one dir, main page]

WO2004066949A8 - Oligonucleotides anti-sens inhibant l'expression du hif-1 - Google Patents

Oligonucleotides anti-sens inhibant l'expression du hif-1

Info

Publication number
WO2004066949A8
WO2004066949A8 PCT/US2004/002344 US2004002344W WO2004066949A8 WO 2004066949 A8 WO2004066949 A8 WO 2004066949A8 US 2004002344 W US2004002344 W US 2004002344W WO 2004066949 A8 WO2004066949 A8 WO 2004066949A8
Authority
WO
WIPO (PCT)
Prior art keywords
hif
inhibit expression
antisense oligonucleotides
cell lines
cancer cell
Prior art date
Application number
PCT/US2004/002344
Other languages
English (en)
Other versions
WO2004066949A3 (fr
WO2004066949A2 (fr
Inventor
Heejeong Yoon
Lingjun Mao
Young Bok Lee
Chang-Ho Ahn
Xiaoming Jiang
Original Assignee
Rexahn Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rexahn Corp filed Critical Rexahn Corp
Priority to CA2513398A priority Critical patent/CA2513398C/fr
Priority to DE602004022921T priority patent/DE602004022921D1/de
Priority to JP2006503098A priority patent/JP4546454B2/ja
Priority to AT04706034T priority patent/ATE441710T1/de
Priority to AU2004207576A priority patent/AU2004207576B8/en
Priority to BR0407070-4A priority patent/BRPI0407070A/pt
Priority to EP04706034A priority patent/EP1601325B1/fr
Publication of WO2004066949A2 publication Critical patent/WO2004066949A2/fr
Publication of WO2004066949A8 publication Critical patent/WO2004066949A8/fr
Publication of WO2004066949A3 publication Critical patent/WO2004066949A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Communicable Diseases (AREA)
  • Biochemistry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne de nouveaux composés oligonucléotidiques anti-sens, RX-0047 et RX-0149, qui inhibent l'expression du HIF-1 et induisent également une cytotoxicité dans plusieurs lignées cellulaires cancéreuses.
PCT/US2004/002344 2003-01-28 2004-01-28 Oligonucleotides anti-sens inhibant l'expression du hif-1 WO2004066949A2 (fr)

Priority Applications (7)

Application Number Priority Date Filing Date Title
CA2513398A CA2513398C (fr) 2003-01-31 2004-01-28 Oligonucleotides anti-sens inhibant l'expression du hif-1
DE602004022921T DE602004022921D1 (de) 2003-01-31 2004-01-28 Antisense oligonukleotide, die die ausprägungsstufe von hif-1 hemmen
JP2006503098A JP4546454B2 (ja) 2003-01-28 2004-01-28 Ｈｉｆ−１発現を抑制するアンチセンスオリゴヌクレオチド
AT04706034T ATE441710T1 (de) 2003-01-31 2004-01-28 Antisense oligonukleotide, die die ausprägungsstufe von hif-1 hemmen
AU2004207576A AU2004207576B8 (en) 2003-01-28 2004-01-28 Antisense oligonucleotides that inhibit expression of HIF-1
BR0407070-4A BRPI0407070A (pt) 2003-01-31 2004-01-28 Oligonucleotìdeos antisentido que inibem a expressão de hif-1
EP04706034A EP1601325B1 (fr) 2003-01-31 2004-01-28 Oligonucleotides anti-sens inhibant l'expression du hif-1

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US76618503A 2003-01-28 2003-01-28
US10/766,185 2003-01-28
US44436703P 2003-01-31 2003-01-31
US60/444,367 2003-01-31

Publications (3)

Publication Number Publication Date
WO2004066949A2 WO2004066949A2 (fr) 2004-08-12
WO2004066949A8 true WO2004066949A8 (fr) 2004-11-11
WO2004066949A3 WO2004066949A3 (fr) 2005-12-01

Family

ID=32829853

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2004/002344 WO2004066949A2 (fr) 2003-01-28 2004-01-28 Oligonucleotides anti-sens inhibant l'expression du hif-1

Country Status (3)

Country Link
JP (1) JP4546454B2 (fr)
AU (1) AU2004207576B8 (fr)
WO (1) WO2004066949A2 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012091496A2 (fr) 2010-12-30 2012-07-05 Samyang Biopharmaceuticals Corporation Arnsi destiné à l'inhibition de l'expression du hif1α et composition anticancéreuse contenant celui-ci
BR112014027834A2 (pt) 2012-05-23 2017-08-08 Univ Ohio State composições de nanopartícula lipídica para entrega de oligonucleotídeos antissenso

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5882914A (en) 1995-06-06 1999-03-16 The Johns Hopkins University School Of Medicine Nucleic acids encoding the hypoxia inducible factor-1
EP1189611B1 (fr) * 1999-06-14 2006-05-03 Cancer Research Technology Limited Therapie anticancereuse
US7105656B2 (en) * 2000-10-26 2006-09-12 The Brigham And Women's Hospital, Inc. Compositions and methods for treating hematologic malignancies and multiple drug resistance
HUE037352T2 (hu) * 2002-04-05 2018-08-28 Roche Innovation Ct Copenhagen As A HIF-1alfa expresszálódását módosító oligomer vegyületek
US7144999B2 (en) * 2002-11-23 2006-12-05 Isis Pharmaceuticals, Inc. Modulation of hypoxia-inducible factor 1 alpha expression

Also Published As

Publication number Publication date
JP2006520195A (ja) 2006-09-07
AU2004207576B2 (en) 2008-10-23
JP4546454B2 (ja) 2010-09-15
AU2004207576B8 (en) 2008-11-20
AU2004207576A1 (en) 2004-08-12
WO2004066949A3 (fr) 2005-12-01
WO2004066949A2 (fr) 2004-08-12

Similar Documents

Publication Publication Date Title
WO2007064945A3 (fr) Therapies contre le cancer et compositions pharmaceutiques utilisees dans ces therapies
AU2003290597A1 (en) Modified oligonucleotides for use in rna interference
WO2007031319A8 (fr) Compositions comprenant des oligonucleotides d'arn a immunostimulation et procedes pour produire lesdits oligonucleotides d'arn
WO2003064625A3 (fr) Compositions oligonucleotidiques presentant une efficacite amelioree
GB2442373B (en) Sequence -specific inhibition of small rna function
WO2007076423A3 (fr) INHIBITEURS D’ACTIVITE Akt
WO2005118824A8 (fr) Methodes et compositions inhibant l'expression genique
WO2004016215A3 (fr) Utilisation d'oligonucleotides antisens pour inhiber l'expression de akt-1
WO2005001039A3 (fr) Production de petits arn interferents (arnsi) regulee par les ribozymes et procedes d'utilisation de ceux-ci
ATE441710T1 (de) Antisense oligonukleotide, die die ausprägungsstufe von hif-1 hemmen
IL171968A0 (en) Difluoromethylbenzanilides and use thereof for combating micro-organisms, intermediate products and use thereof
EP1581653A4 (fr) Elimination de cellule ciblee par l'intermediaire d'un arn double brin
IL178764A0 (en) ANTISENSE OLIGONUCLEOTIDES AGAINST cPLA2, COMPOSITIONS AND USES THEREOF
WO2004066949A8 (fr) Oligonucleotides anti-sens inhibant l'expression du hif-1
WO2007065017A3 (fr) Systeme d'administration de liposomes cationiques a oligonucleotides
AU2003292227A1 (en) Combined antisense oligonucleotide cancer therapy
IL182280A0 (en) Single stranded antimicrobial oligonucleotides and uses thereof
WO2005025487A3 (fr) Oligonucleotides ciblant les maladies a prions
EP1613722A4 (fr) Oligonucleotides inhibiteurs a base d'arn
ZA200308879B (en) Skin Lotion.
AU2003298465A1 (en) Selective hydrogenation of nitrogen containing aromatics
WO2003074060A3 (fr) Combinaison chimiothérapie et antisens de la dna déméthylase
AU2003275143A1 (en) Triplex hairpin ribozyme
EP1707630A4 (fr) Oligonucleotide antisens presentant une activite anticancereuse
AU2003218555A1 (en) Combinations of antisense oligonucleotides directed against thymidylate synythase mrna and uses thereof

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
CFP Corrected version of a pamphlet front page
CR1 Correction of entry in section i

Free format text: IN PCT GAZETTE 33/2004 UNDER (30) DELETE "10/766,18, 28 JANUARY 2003 (28.01.2003), US"

WWE Wipo information: entry into national phase

Ref document number: 2513398

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2004207576

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 1020057013673

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 2006503098

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 20048032331

Country of ref document: CN

WWE Wipo information: entry into national phase

Ref document number: 2004706034

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2004207576

Country of ref document: AU

DPEN Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101)
WWP Wipo information: published in national office

Ref document number: 1020057013673

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: 2004706034

Country of ref document: EP

ENP Entry into the national phase in:

Ref document number: PI0407070

Country of ref document: BR